247 related articles for article (PubMed ID: 33359567)
1. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
2. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.
Cramer JD; Ferris RL; Kim S; Duvvuri U
Oral Oncol; 2018 Dec; 87():170-176. PubMed ID: 30527235
[TBL] [Abstract][Full Text] [Related]
3. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311).
Ferris RL; Flamand Y; Weinstein GS; Li S; Quon H; Mehra R; Garcia JJ; Chung CH; Gillison ML; Duvvuri U; O'Malley BW; Ozer E; Thomas GR; Koch WM; Gross ND; Bell RB; Saba NF; Lango M; Méndez E; Burtness B
J Clin Oncol; 2022 Jan; 40(2):138-149. PubMed ID: 34699271
[TBL] [Abstract][Full Text] [Related]
4. Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis.
Sher DJ; Yan J; Day AT; Khan S; Zhu H
Oral Oncol; 2021 Jan; 112():105029. PubMed ID: 33142225
[TBL] [Abstract][Full Text] [Related]
5. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Ma DJ; Price KA; Moore EJ; Patel SH; Hinni ML; Garcia JJ; Graner DE; Foster NR; Ginos B; Neben-Wittich M; Garces YI; Chintakuntlawar AV; Price DL; Olsen KD; Van Abel KM; Kasperbauer JL; Janus JR; Waddle M; Miller R; Shiraishi S; Foote RL
J Clin Oncol; 2019 Aug; 37(22):1909-1918. PubMed ID: 31163012
[TBL] [Abstract][Full Text] [Related]
6. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
Misiukiewicz K; Gupta V; Miles BA; Bakst R; Genden E; Selkridge I; Surgeon JT; Rainey H; Camille N; Roy E; Zhang D; Ye F; Jia R; Moshier E; Bonomi M; Hwang M; Som P; Posner MR
Oral Oncol; 2019 Aug; 95():170-177. PubMed ID: 31345387
[TBL] [Abstract][Full Text] [Related]
7. Radiation therapy dose de-escalation compared to standard dose radiation therapy in definitive treatment of HPV-positive oropharyngeal squamous cell carcinoma.
Gabani P; Lin AJ; Barnes J; Oppelt P; Adkins DR; Rich JT; Zevallos JP; Daly MD; Gay HA; Thorstad WL
Radiother Oncol; 2019 May; 134():81-88. PubMed ID: 31005228
[TBL] [Abstract][Full Text] [Related]
8. Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS.
Carey RM; Brody RM; Shimunov D; Shinn JR; Mady LJ; Rajasekaran K; Cannady SB; Lin A; Lukens JN; Bauml JM; Cohen RB; Basu D; O'Malley BW; Weinstein GS; Newman JG
Laryngoscope; 2021 Dec; 131(12):E2865-E2873. PubMed ID: 34076275
[TBL] [Abstract][Full Text] [Related]
9. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
10. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes and survival following definitive (chemo)radiotherapy in HPV-positive oropharynx cancer: Large-scale comparison of DAHANCA vs PMH cohorts.
Lassen P; Huang SH; Su J; Waldron J; Andersen M; Primdahl H; Johansen J; Kristensen CA; Andersen E; Eriksen JG; Hansen CR; Alsner J; Lilja-Fisher J; Bratman SV; Ringash J; Kim J; Hope A; Spreafico A; de Almeida J; Xu W; O'Sullivan B; Overgaard J
Int J Cancer; 2022 Apr; 150(8):1329-1340. PubMed ID: 34792199
[TBL] [Abstract][Full Text] [Related]
12. Treatment Modality Impact on Patient-Reported Quality of Life in Human Papilloma Virus-Associated Oropharyngeal Carcinoma.
Plonowska-Hirschfeld KA; Gulati A; Stephens EM; Ochoa E; Xu MJ; Ha PK; Heaton CM; Yom SS; Chan JW; Algazi A; Kang H; Ryan WR
Laryngoscope; 2024 Apr; 134(4):1687-1695. PubMed ID: 37767815
[TBL] [Abstract][Full Text] [Related]
13. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.
Kelly JR; Park HS; An Y; Yarbrough WG; Contessa JN; Decker R; Mehra S; Judson BL; Burtness B; Husain Z
Oral Oncol; 2018 Apr; 79():64-70. PubMed ID: 29598952
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era.
Sher DJ; Nedzi L; Khan S; Hughes R; Sumer BD; Myers LL; Truelson JM; Koshy M
JAMA Otolaryngol Head Neck Surg; 2016 Aug; 142(8):777-88. PubMed ID: 27368076
[TBL] [Abstract][Full Text] [Related]
15. Utilization of Transoral Robotic Surgery (TORS) in patients with Oropharyngeal Squamous Cell Carcinoma and its impact on survival and use of chemotherapy.
Baliga S; Kabarriti R; Jiang J; Mehta V; Guha C; Kalnicki S; Smith RV; Garg MK
Oral Oncol; 2018 Nov; 86():75-80. PubMed ID: 30409323
[TBL] [Abstract][Full Text] [Related]
16. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Chemoradiation Therapy Versus Transoral Robotic Surgery for Human Papillomavirus-Associated, Clinical N2 Oropharyngeal Cancer.
Sher DJ; Fidler MJ; Tishler RB; Stenson K; al-Khudari S
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):512-22. PubMed ID: 26867880
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Chemoradiation After Surgical Resection in Elderly Patients With High-Risk Squamous Cell Carcinoma of the Head and Neck: A National Cancer Database Analysis.
Woody NM; Ward MC; Koyfman SA; Reddy CA; Geiger J; Joshi N; Burkey B; Scharpf J; Lamarre E; Prendes B; Adelstein DJ
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):784-792. PubMed ID: 28602410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
